Alto Neuroscience reported net income of -$27.64M for the quarter ended Jun 2026. This income statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 3.76M | 3.77M | 3.80M | 3.83M | 17.60M | 26.95M | 26.97M | 26.99M | 27.07M | 27.07M | 27.17M | 31.92M | 35.05M | 35.09M |
| Operating items | ||||||||||||||
| Research & DevelopmentR&D | 5.61M | 7.07M | 7.97M | 9.64M | 9.95M | 13.18M | 13.06M | 10.80M | 9.97M | 13.12M | 10.53M | 12.00M | 20.29M | 22.11M |
| Selling, General & AdministrativeSG&A | 1.59M | 2.05M | 1.75M | 2.12M | 4.43M | 5.16M | 5.83M | 6.20M | 5.70M | 5.56M | 4.43M | 5.06M | 6.84M | 7.02M |
| Operating ExpensesOpex | 7.20M | 9.12M | 9.72M | 11.77M | 14.39M | 18.34M | 18.89M | 17.00M | 15.68M | 18.68M | 14.95M | 17.05M | 27.14M | 29.13M |
| Operating IncomeOp. Inc | -7.20M | -9.12M | -9.72M | -11.77M | -14.39M | -18.34M | -18.89M | -17.00M | -15.68M | -18.68M | -14.95M | -17.05M | -27.14M | -29.13M |
| EBIT | -7.20M | -9.12M | -9.72M | -11.77M | -14.39M | -18.34M | -18.89M | -17.00M | -15.68M | -18.68M | -14.95M | -17.05M | -27.14M | -29.13M |
| Non-operating items | ||||||||||||||
| Non Operating Interest Expenses | 0.32M | 0.33M | 0.36M | 0.36M | 0.35M | 0.35M | 0.35M | 0.33M | 0.60M | 0.65M | 0.65M | 0.57M | 0.55M | 0.49M |
| Interest & Investment IncomeInt & Inv Inc | 0.23M | 0.67M | 0.71M | 0.74M | 1.56M | 2.66M | 2.50M | 2.13M | 1.83M | 1.68M | 1.53M | 1.56M | 1.56M | 2.11M |
| Other Non Operating IncomeOther Non Op Inc. | -0.68M | |||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.08M | 0.46M | 0.58M | 0.55M | 0.97M | 2.31M | 2.10M | 1.80M | 0.51M | 0.98M | 0.77M | 0.87M | 0.90M | 1.49M |
| Net income details | ||||||||||||||
| EBT | -7.29M | -8.79M | -9.37M | -11.38M | -13.17M | -16.03M | -16.73M | -15.20M | -14.45M | -17.64M | -14.07M | -16.07M | -26.12M | -27.51M |
| Profit After TaxPAT | -7.28M | -8.66M | -9.14M | -11.22M | -13.42M | -16.03M | -16.78M | -15.20M | -15.17M | -17.71M | -14.18M | -16.18M | -26.24M | -27.64M |
| Income from Continuing OperationsIncome (Continuing) | -7.29M | -8.79M | -9.37M | -11.38M | -13.17M | -16.03M | -16.73M | -15.20M | -14.45M | -17.64M | -14.07M | -16.07M | -26.12M | -27.51M |
| Consolidated Net IncomeConsol Net Inc. | -7.29M | -8.79M | -9.37M | -11.38M | -13.17M | -16.03M | -16.73M | -15.20M | -14.45M | -17.64M | -14.07M | -16.07M | -26.12M | -27.51M |
| Income towards Parent CompanyParent Net Inc | -7.29M | -8.79M | -9.37M | -11.38M | -13.17M | -16.03M | -16.73M | -15.20M | -14.45M | -17.64M | -14.07M | -16.07M | -26.12M | -27.51M |
| Net Income towards Common StockholdersNet Income | -7.29M | -8.79M | -9.37M | -11.38M | -13.17M | -16.03M | -16.73M | -15.20M | -14.45M | -17.64M | -14.07M | -16.07M | -26.12M | -27.51M |
| Additional items | ||||||||||||||
| EPS (Basic) | -1.98 | -2.36 | -2.50 | -3.05 | -0.75 | -0.60 | -0.62 | -0.62 | -0.53 | -0.65 | -0.52 | -0.56 | -0.79 | -0.64 |
| EPS (Diluted) | -1.98 | -2.36 | -2.50 | -3.05 | -0.75 | -0.60 | -0.62 | -0.62 | -0.53 | -0.65 | -0.52 | -0.56 | -0.79 | -0.64 |
| Shares Outstanding | 3.69M | 3.72M | 3.74M | 3.73M | 17.60M | 26.91M | 26.96M | 24.60M | 27.05M | 27.07M | 27.10M | 28.85M | 32.89M | 42.81M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 3.69M | 3.72M | 3.74M | 3.73M | 17.60M | 26.91M | 26.96M | 24.60M | 27.05M | 27.07M | 27.10M | 28.85M | 32.89M | 42.81M |
| EBITDA | -7.20M | -9.12M | -9.72M | -11.77M | -14.39M | -18.34M | -18.89M | -17.00M | -15.68M | -18.68M | -14.95M | -17.05M | -27.14M | -29.13M |
| Interest ExpensesInt Expense | 0.32M | 0.33M | 0.36M | 0.36M | 0.35M | 0.35M | 0.35M | 0.33M | 0.60M | 0.65M | 0.65M | 0.57M | 0.55M | 0.49M |